Almarys is listed on the Official Market of the Stock Exchange of Mauritius. The company holds 13,300 arpents of strategically located agricultural land and a 25.38% equity stake in Société Helicophanta. Through investment in Almarys, shareholders access a strategic minority stake in a world-class biotech company offering both recurring cash flows and medium-term growth potential.
Almarys offers a blend of asset-backed security and innovative growth opportunities to its shareholders.
The Annual report 2026 covers the first year of Almarys Limited as a land and investment holding company. The Company manages around 13,300 arpents of land and holds a 25% stake in Société Helicophanta, which is developing biomedical operations in the United States.
For the year ended 30 June 2026, Almarys posted a profit of MUR 1.3 billion, including MUR 948 million in fair value gains on land. Net asset value stood at MUR 40.36 per share. The Board declared a total dividend of MUR 0.18 per share.
The report sets out how Almarys plans to build value from both.
Strong asset base
Shareholders will own a company with significant land holdings.
Stable recurring revenue
Consistent cash flows from Société Helicophanta and the rental of land.
Long-term growth potential
Appreciation potential of land holdings; strategic entry into the emerging biotechnology sector.
Almarys is listed on the Official Market of the Stock Exchange of Mauritius. The Company holds 13,300 arpents of agricultural land and a 25.38% equity stake in Société Helicophanta.
Copyright © 2026 Almarys | Concept and Development by Diizz
